AKEBIA THERAPEUTICS, INC. (AKBA) Operating Margin
- Operating margin · 12 months: Value -6.90%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -6.90% | Operating income / revenue. Period ending 2026-06-30. $-15.13M ÷ $219.06M × 100 ≈ -6.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -15.13M USD | Operating Income (Loss) |
| Revenue | 219.06M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 70.46M USD | Research and Development Expense |
| Selling, general and administration | 113.79M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-15.13M | $219.06M | (m) | $70.46M | $113.79M | -6.90% |
| 2026-03-31 | $5.29M | $232.40M | (m) | $67.41M | $112.17M | 2.28% |
| 2025-12-31 | $23.50M | $236.20M | (m) | $62.36M | $107.48M | 9.95% |
| 2025-09-30 | $17.75M | $225.07M | (m) | $47.50M | $109.07M | 7.88% |
| 2025-06-30 | $791.00K | $203.73M | (m) | $41.04M | $106.49M | 0.39% |
| 2025-03-31 | $-22.02M | $184.91M | (m) | $37.67M | $106.85M | -11.91% |
| 2024-12-31 | $-50.47M | $160.18M | (m) | $37.65M | $106.55M | -31.51% |
| 2024-09-30 | $-34.79M | $169.88M | (m) | $35.73M | $104.31M | -20.48% |
| 2024-06-30 | $-35.32M | $174.50M | (m) | $40.58M | $100.50M | -20.24% |
| 2024-03-31 | $-35.59M | $187.22M | (m) | $53.12M | $100.62M | -19.01% |
| 2023-12-31 | $-46.26M | $194.62M | (m) | $63.08M | $100.23M | -23.77% |
| 2023-09-30 | $-52.50M | $194.21M | (m) | $85.31M | $104.70M | -27.03% |
| 2023-06-30 | $-89.87M | $200.88M | (m) | $100.01M | $113.89M | -44.74% |
| 2023-03-31 | $-45.56M | $271.03M | (m) | $104.97M | $119.59M | -16.81% |
| 2022-12-31 | $-79.11M | $292.60M | (m) | $129.11M | $138.70M | -27.04% |
| 2022-09-30 | $-138.92M | $297.03M | (m) | $126.77M | $152.88M | -46.77% |
| 2022-06-30 | $-145.63M | $296.82M | (m) | $139.89M | $168.32M | -49.06% |
| 2022-03-31 | $-258.88M | $222.97M | (m) | $151.07M | $177.16M | -116.10% |
| 2021-12-31 | $-265.32M | $213.58M | (m) | $147.85M | $174.16M | -124.23% |
| 2021-09-30 | $-284.57M | $210.67M | (m) | $155.87M | $169.65M | -135.08% |
| 2021-06-30 | $-287.77M | $221.90M | (m) | $162.26M | $163.46M | -129.68% |
| 2021-03-31 | $-382.25M | $259.13M | (m) | $177.87M | $157.29M | -147.51% |
| 2020-12-31 | $-376.44M | $295.31M | (m) | $218.49M | $153.95M | -127.47% |
| 2020-09-30 | $-385.93M | $308.16M | (m) | $261.32M | $158.55M | -125.24% |
| 2020-06-30 | $-383.74M | $340.15M | (m) | $288.97M | $152.56M | -112.81% |
| 2020-03-31 | $-269.44M | $350.81M | $105.39M | $321.85M | $153.15M | -76.81% |
| 2019-12-31 | $-286.29M | $335.00M | $108.94M | $322.97M | $149.46M | -85.46% |
| 2019-09-30 | $-281.56M | $325.30M | (m) | $329.61M | $159.66M | -86.55% |
| 2019-06-30 | $-253.49M | $286.49M | (m) | $325.73M | $135.86M | -88.48% |
| 2019-03-31 | $-229.63M | $234.48M | (m) | $311.95M | $112.33M | -97.93% |
| 2018-12-31 | $-178.16M | $207.74M | $6.25M | $291.01M | $87.06M | -85.76% |
| 2018-09-30 | $-76.64M | (m) | (m) | $272.34M | (m) | (m) |
| 2018-06-30 | $-72.97M | (m) | (m) | $260.41M | (m) | (m) |
| 2018-03-31 | $-59.44M | (m) | (m) | $232.25M | (m) | (m) |
| 2017-12-31 | $-79.92M | (m) | (m) | $230.89M | (m) | (m) |
| 2017-09-30 | $-129.33M | (m) | (m) | $195.95M | (m) | (m) |
| 2017-06-30 | $-141.33M | (m) | (m) | $168.47M | (m) | (m) |
| 2017-03-31 | $-155.39M | (m) | (m) | $155.60M | (m) | (m) |
| 2016-12-31 | $-136.46M | (m) | (m) | $115.78M | (m) | (m) |
| 2016-09-30 | $-118.47M | $0.00 | (m) | $96.59M | (m) | (m) |
| 2016-06-30 | $-101.96M | $0.00 | (m) | $80.96M | (m) | (m) |
| 2016-03-31 | $-76.66M | $0.00 | (m) | $56.59M | (m) | (m) |
| 2015-12-31 | $-61.51M | $0.00 | (m) | $43.02M | (m) | (m) |
| 2015-09-30 | $-52.07M | $0.00 | (m) | $37.55M | (m) | (m) |
| 2015-06-30 | $-41.98M | (m) | (m) | $28.40M | (m) | (m) |
| 2015-03-31 | $-38.93M | (m) | (m) | $26.75M | (m) | (m) |
| 2014-12-31 | $-37.94M | $0.00 | (m) | $25.40M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-15.93M | (m) | (m) | $10.78M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-8.52M | (m) | (m) | $5.63M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |